Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia

Jonathan Isaacsohn, Donald Hunninghake, Helmut Schrott, Carlos A. Dujovne, Robert Knopp, Stuart R. Weiss, Harold Bays, John R. Crouse, Michael H. Davidson, Leonard M. Keilson, James McKenney, Stanley G. Korenman, Adrian S. Dobs, Evan Stein, Ronald M. Krauss, Darbie Maccubbin, Meehyung Cho, Diane J. Plotkin, Yale B. Mitchel

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Background: Patients with elevated levels of serum triglycerides (TG) often have other associated lipid abnormalities (e.g., low levels of high-density lipoprotein cholesterol [HDL-C]) and are at increased risk of developing coronary heart disease. Although the therapeutic benefits of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in hypercholesterolemic patients have been well established, less is known about the effects of statins in patient populations with hypertriglyceridemia. Hypothesis: The purpose of this study was to evaluate the lipoprotein-altering efficacy of simvastatin in hypertriglyceridemic patients. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study. In all, 195 patients with fasting serum triglyceride levels between 300 and 900 mg/dl received once daily doses of placebo or simvastatin 20, 40, or 80 mg for 6 weeks. Results: Compared with placebo, simvastatin treatment across all doses resulted in significant reductions (p < 0.05 - < 0.001) in serum levels of triglycerides (-20 to -31% decrease) and TG-rich lipoprotein particles. Significant (p < 0.001) reductions were also seen in low-density lipoprotein cholesterol (-25 to -35%) and non-HDL-C (-26 to -40%). Levels of HDL-C were increased (7-11%) in the simvastatin groups compared with placebo (p < 0.05 - < 0.001). Conclusion: The results of this study demonstrate the beneficial effects of simvastatin in patients with hypertriglyceridemia.

Original languageEnglish (US)
Pages (from-to)18-24
Number of pages7
JournalClinical Cardiology
Issue number1
StatePublished - Jan 1 2003


  • 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
  • Hypertriglyceridemia
  • Lipoprotein
  • Simvastatin
  • Triglycerides

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia'. Together they form a unique fingerprint.

Cite this